GATC Biotech subsidiary Lifecodexx has started operational research-and-development work on clinically validated diagnostic tests by using next-generation sequencing technologies.
The work currently focuses on the field of prenatal diagnostics.
Lifecodexx will utilise GATC Biotech's sequencing laboratory, which has a total capacity of more than two terabases per year.
The company intends to establish 'next-generation molecular diagnostics' in Europe.
This will provide improved diagnostics for targeted, cost-efficient treatments.
The test development currently being undertaken also receives public funding, including up to EUR300,000 (GBP260,000) from the Zimsolo and KMU Innovativ funding programmes.
According to Dr Michael Lutz, chief executive officer of the company, Lifecodexx intends to carry out human genetic diagnostic tests based on sequencing technologies.
He believes that this will improve cost efficiency in diagnostics.
